<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370865">
  <stage>Registered</stage>
  <submitdate>8/06/2016</submitdate>
  <approvaldate>30/06/2016</approvaldate>
  <actrnumber>ACTRN12616000858493</actrnumber>
  <trial_identification>
    <studytitle>Pilot trial on the effect of the consumption of gold kiwifruit on glycaemic control in individuals with prediabetes</studytitle>
    <scientifictitle>Effect of the consumption of gold kiwifruit on glycaemic control in individuals with prediabetes</scientifictitle>
    <utrn>U1111-1183-9874 </utrn>
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prediabetes</healthcondition>
    <healthcondition>Dysglycaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All participants will be asked to consume 2 gold kiwifruit (flesh only) with their breakfast every day for 12 weeks. Adherence will be monitored by food diaries and by measurement of vitamin c in blood samples.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HbA1c will be determined in EDTA blood using Biorad Variant HPLC</outcome>
      <timepoint>13 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting glucose will be determined in plasma using the glucose hexokinase enzymatic assay on the Abbott C series analyser.</outcome>
      <timepoint>13 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lipid parameters (total cholesterol (TC), HDL-cholesterol (HDL), LDL-cholesterol (LDL) and triglycerides (TG))</outcome>
      <timepoint>13 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gastrointestinal symptom rating scale (GSRS).  </outcome>
      <timepoint>Weeks 7 and 13 </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hormones (for example, insulin, leptin, ghrelin and adiponectin) </outcome>
      <timepoint>13 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gut microbiota composition</outcome>
      <timepoint>13 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria: Selection criteria for trial participants will be the requirement to meet the diagnostic criteria for prediabetes according to the American Diabetes Association (ADA) criteria for glycated haemoglobin (HbA1c).  All participants will be free living and required to maintain their normal dietary and lifestyle habits for the duration of the trial.
ADA criteria for the diagnosis of prediabetes: HbA1c: 39-46 mmol/mol inclusive.  
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria: 
a.Individuals unable to give informed consent.
b. Those with an HbA1c outside the range of 39-46 mmol/mol.
c. Those with a previous diagnosis of diabetes. 
d. Those on diabetes medications such as Metformin. 
e.Those that have taken antibiotics within a month prior to the trial starting. 
f.Those with a known kiwifruit allergy. 
g.Those with a medical history of significant gastrointestinal disease for example, coeliac disease, inflammatory bowel disease or a previous bowel resection.
h.Women who are pregnant, breastfeeding or planning a pregnancy in the 3 months post selection (trial period) will be excluded.
i.Those who have a planned trip overseas in the 3 months post selection will be excluded.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Nil</concealment>
    <sequence>Nil</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>This is a pilot exploratory study. Summary statistics (mean, SD, SEM, 95% CI) will be reported for all continuous variables.  Median (plus interquartile range) will be reported for non-normally distributed data, and categorical variables, such as low or high diversity among gut microbial species,  will be presented as numbers and percentages.  Comparisons of baseline and end of study measures, such as HbA1c, will be made to determine if there are any statistical and clinical differences. </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/08/2016</anticipatedenddate>
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>PO Box 56
Dunedin, 9054
New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Zespri International Ltd</fundingname>
      <fundingaddress>40 Maunganui Road
Mt Maunganui
New Zealand 3116</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if consumption of two gold kiwifruit per day for 12 weeks favourably alters gut microbiota composition without adversely affecting blood glucose control in people with pre-diabetes.. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Health and Disability Ethics Committees
Ministry of Health
Freyberg Building
P O Box 5013
Wellington 6011</ethicaddress>
      <ethicapprovaldate>15/06/2016</ethicapprovaldate>
      <hrec>16/STH/87</hrec>
      <ethicsubmitdate>9/06/2016</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Richard Gearry</name>
      <address>Department of Medicine
University of Otago Christchurch Campus
2 Riccarton Avenue
P O Box 4345
Christchurch 8011</address>
      <phone>+64 3 3640 530</phone>
      <fax>+64 3 3640 525</fax>
      <email>richard.gearry@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Renee Wilson</name>
      <address>Don Beaven Medical Research Centre, 
Christchurch Hospital Campus,
Level 2, 40 Stewart Street
Private Bag 4710, 
Christchurch 8140
</address>
      <phone>+64 3 3640 449</phone>
      <fax>+64 3 3640 457</fax>
      <email>renee.wilson@postgrad.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Renee Wilson</name>
      <address>Don Beaven Medical Research Centre, 
Christchurch Hospital Campus,
Level 2, 40 Stewart Street
Private Bag 4710, 
Christchurch 8140
</address>
      <phone>+64 3 3640 449</phone>
      <fax>+64 3 3640 457</fax>
      <email>renee.wilson@postgrad.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jinny Willis</name>
      <address>Don Beaven Medical Research Centre, 
Christchurch Hospital Campus,
Level 2, 40 Stewart Street
Private Bag 4710, 
Christchurch 8140
</address>
      <phone>+64 3 3640 448</phone>
      <fax>+64 3 3640 457</fax>
      <email>jinny.willis@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>